The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | TNB-486: a novel BiTE being explored in R/R B-NHL
Ranjit Nair, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a Phase I trial evaluating TNB-486, a novel CD19xCD3 bispecific T-cell engager (BiTE), in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL; NCT04594642). Dr Nair first discusses the mechanism of action of this agent, and then goes on to explain the inclusion criteria for this study. Following this, Dr Nair highlights the safety and efficacy of this agent. Adverse events (AEs) were manageable and this agent was well-tolerated, with lymphopenia and neutropenia being the most common side effects observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte Corporation: Honoraria.
